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Type I interferon (IFN-I) promotes antiviral CD8+T cell
responses, but the contribution of different IFN-I
sources and signaling pathways are ill defined. While
plasmacytoid dendritic cells (pDCs) produce IFN-I
upon TLR stimulation, IFN-I is induced in most cells
by helicases like MDA5. Using acute and chronic
lymphocytic choriomeningitis virus (LCMV) infection
models, we determined that pDCs transiently pro-
duce IFN-I that minimally impacts CD8+T cell re-
sponses and viral persistence. Rather, MDA5 is the
key sensor that induces IFN-I required for CD8+T
cell responses. In the absence of MDA5, CD8+T cell
responses to acute infection rely on CD4+T cell
help, and loss of both CD4+T cells and MDA5 results
in CD8+T cell exhaustion and persistent infection.
Chronic LCMV infection rapidly attenuates IFN-I
responses, but early administration of exogenous
IFN-I rescues CD8+T cells, promoting viral clear-
ance. Thus, effective antiviral CD8+T cell responses
depend on the timing and magnitude of IFN-I
production.
INTRODUCTION
Type I interferon (IFN-I), i.e., IFN-a/b, plays dual roles during
the host response to viruses: it provides innate defense and
promotes adaptive CD8 T cell responses (Garcı´a-Sastre and
Biron, 2006; Trinchieri, 2010). IFN-I impacts CD8 T cells at
several levels: it promotes priming by enhancing the capacity
of dendritic cells (DC) to process and present viral antigens
(Le Bon et al., 2003; Le Bon and Tough, 2008); it boosts the
capacity of CD8 T cells to secrete mediators such as perforin
and granzyme that lyse infected cells; and it promotes the
survival of memory CD8 T cells (Kolumam et al., 2005; Marrack
et al., 1999; Thompson et al., 2006; Tough et al., 1996).
Viruses trigger an IFN-I response in most cells by stimulating
sensors that detect viral nucleic acids. Among these, the RIG-
I-like receptors (RLR), including RIG-I and MDA5, are helicases
that detect distinct forms of viral RNA in the cytosol of infectedCell Hcells and activate the adaptor IPS1, which initiates a downstream
signaling pathway that leads to IFN-I secretion (Pichlmair and
Reis e Sousa, 2007; Takeuchi and Akira, 2010). IFN-I is also
produced by specialized antigen-presenting cells, known as
plasmacytoid dendritic cells (pDC). pDCs sense viruses through
Toll-like receptor (TLR) 7 and TLR9 (Gilliet et al., 2008). TLR7 and
TLR9 detect viral RNA and DNA, respectively, and transduce
downstream signals through the adaptor MyD88, triggering
secretion of IFN-I (Pichlmair and Reis e Sousa, 2007; Takeuchi
and Akira, 2010). In contrast to cytosolic RLRs, TLR7 and
TLR9 are located in a specialized endosomal compartment
(Barbalat et al., 2011; Blasius and Beutler, 2010). Thus, pDCs
detect external viral particles that have been captured by endo-
cytosis (Wang et al., 2007) or cytosolic viral particles that
become enclosed in a vacuole during autophagy (Lee et al.,
2007).
While it has been established that IFN-I is critical for the gener-
ation of CD8 T cell responses (Garcı´a-Sastre and Biron, 2006;
Haring et al., 2006; Mescher et al., 2006; Trinchieri, 2010), the
impact of disparate sources and signaling pathways of IFN-I
during this process remains poorly understood. pDCs facilitate
the accumulation of virus-specific CD8 T cells during vesicular
stomatitis virus (VSV) infection (Swiecki et al., 2010). The gener-
ation of a CD8 T cell response during lymphocytic choriomenin-
gitis virus (LCMV) infection requires MyD88 (Jung et al., 2008;
Zhou et al., 2005), but it is not clear whether this requirement
reflects the involvement of pDCs. In contrast, antiviral CD8
T cells are not dependent on either the MyD88 or IPS-1 signaling
pathways during influenza A virus infection (Koyama et al., 2007),
excluding a role for pDCs and RLRs. Thus, it is likely that pDCs
and/or RLRs influence on CD8 T cell responses may vary during
diverse viral infections.
To more precisely define the impact of disparate sources of
IFN-I on the generation of antiviral CD8 T cell responses, we
chose to study LCMV infection in themouse. LCMV is a noncyto-
pathic RNA virus that elicits acute or chronic infection depending
on the viral strain (Oldstone, 2002; Zinkernagel, 2002). Infection
with LCMV Armstrong (ARM) elicits a strong CD8 T cell response
that controls viral replication, resulting in clearance of the infec-
tion. LCMV CL13 (CL13) has a broader replicative capacity and
tropism for target cells, which include DCs, hematopoietic
progenitor cells, and fibroblasts than ARM (Bergthaler et al.,
2010; Borrow et al., 1995; Macal et al., 2012; Mueller et al.,
2007; Sevilla et al., 2000, 2004). The CD8 T cell response duringost & Microbe 11, 631–642, June 14, 2012 ª2012 Elsevier Inc. 631
Figure 1. Contribution of pDCs to IFN-I and
CD8 T Cell Responses to LCMV (See Also
Figure S1)
(A–E) BDCA2-DTR (DTR) mice treated with PBS or
DT were infected with ARM (A) or CL13 (B) and
serum IFN-awasmeasured at different time points
p.i. Frequencies of pDCs in spleens of WT mice
infectedwith either ARMor CL13 on day 2 p.i. were
compared to frequencies of pDCs in naive mice
(day 0) (C). DTRmice were injected with PBS or DT
during the first week of infection with CL13 to
deplete pDCs, and viral titers in the spleen were
determined (D). Dots on the right side of the hash
mark indicate CL13 titers on day 29 p.i. in spleens
of mice treated with PBS or DT for the entire
duration of the experiment (chronic depletion,
C.D.). (E) Total number of GP33-41-specific CD8
T cells in spleens of PBS or DT-treated mice
infected with CL13. Data are representative
of experiments that were repeated 2–4 times.
**** = p < 0.0001; *** = p < 0.001; * = p < 0.05,
Student’s t test.
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ing in persistent infection and exhaustion of CD8 T cells, which
are either deleted or unable to produce cytolytic mediators and
cytokines (Moskophidis et al., 1993; Wherry, 2011; Zajac et al.,
1998).
It has been shown that IFN-I is essential for the generation of
effective anti-LCMV CD8 T cells (Kolumam et al., 2005; Mosko-
phidis et al., 1994; Mu¨ller et al., 1994; Ou et al., 2001; Thompson
et al., 2006; van den Broek et al., 1995a). Thus, LCMV provides
the opportunity to evaluate the impact of disparate viral sensors
and sources of IFN-I on CD8 T cell responses in settings of acute
or chronic viral infection. Results presented here demonstrate
that the impact of pDCs and RLRs on anti-LCMV CD8 T cell
responses depends on the timing and magnitude of the IFN-I
response they mediate.
RESULTS
pDCs Are an Early and Transient Source of IFN-I during
LCMV Infection
The role of pDCs during LCMV infection is controversial. It has
been shown that LCMV stimulates pDC production of IFN-I
(Jung et al., 2008; Montoya et al., 2005) by activating a pathway
that depends upon MyD88 and, in part, TLR7 and TLR9 (Jung
et al., 2008). However, another study indicated that the IFN-I
response to LCMV is largely pDC-independent (Dalod et al.,
2002). Moreover, it has been shown that CL13 impairs pDC
function, contributing to immunosuppression (Bergthaler et al.,
2010; Lee et al., 2009a; Zuniga et al., 2008). We assessed the
role of pDCs in anti-LCMV defense using BDCA2-DTR trans-
genic mice, in which pDCs can be specifically depleted by
administration of diphtheria toxin (DT) (Figure S1A) (Swiecki632 Cell Host & Microbe 11, 631–642, June 14, 2012 ª2012 Elsevier Inc.et al., 2010). Mice were treated with DT
or PBS to eliminate pDCs or not during
infection with ARM or CL13. Serum
IFN-a and viral titers were determined at
various time points postinfection (p.i.).Both ARM and CL13 infection induced an IFN-a response that
was detectable 16 hr p.i., optimal at 24–48 hr p.i. (Figures 1A
and 1B), and rapidly declined to undetectable levels 4–5 days
p.i. (data not shown). Depletion of pDCs reduced serum IFN-a
levels at 16 hr p.i., but not at later time points (Figures 1A
and 1B). Consistent with the transient effect of pDCs on systemic
IFN-I responses, we observed a marked reduction in pDC
frequencies in the spleen of ARM and CL13 infected mice 48 hr
p.i. (Figure 1C). This reduction in pDC numbers most likely
reflects pDC death due to IFN-I-induced apoptosis, which we
recently reported in other systemic viral infections (Swiecki
et al., 2011).
In agreement with the rapid disappearance of pDCs during
LCMV infection, pDC depletion had no major impact on LCMV
titers during chronic infection except for a slight increase of viral
titers at 48 hr p.i. (Figure 1D). Moreover, pDC depletion did not
affect the generation of GP33-41-specific CD8 T cells in the
spleens of CL13-infected mice (Figures 1E and S1B). In fact,
absolute numbers of GP33-41-specific CD8 T cells were slightly
increased on day 7 p.i., probably reflecting the transient increase
in viral titers and antigen availability. We also extended pDC
depletion throughout days 28–30 p.i. during chronic CL13 infec-
tion, assuming that pDCsmay recover and produce low amounts
of IFN-a that are not detectable in the serum. Prolonged pDC
depletion had no major effect on viral titers or GP33-41-specific
CD8 T cells (Figures 1D and S1B), although we did note a
more pronounced reduction in spleen cellularity than that
observed in untreated mice (Figure S1C). These results demon-
strate that pDCs have an early but limited impact on the ampli-
tude and duration of IFN-a responses to LCMV and no significant
effect on CD8 T cell responses or viral persistence at least until
day 30 p.i.
Figure 2. Contribution of TLR7/MyD88 and
MDA5 Pathways to IFN-I Production during
LCMV Infection
(A–E) Serum IFN-a in response to ARM (A–C) or
CL13 (D and E) at various time points p.i. Two to
ten mice frommultiple experiments were analyzed
for each time point. The dotted lines in (A) and
(D) indicate IFN-a baseline in serum from unin-
fectedmice. Error bars represent themean ± SEM.
**** = p < 0.0001; *** = p < 0.001; ** = p < 0.01;
* = p < 0.05, Student’s t test.
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Infection Depend on MDA5
A MyD88-dependent (Jung et al., 2008) and an MDA5-depen-
dent pathway (Zhou et al., 2010) have been implicated in the
IFN-I response to LCMV infection; however, the relative impor-
tance of each is not known. We first investigated this issue in
acute LCMV infection. We inoculated WT, TRIF/ x MyD88/
(TxM)/ and MDA5/ mice with ARM and determined serum
IFN-a at different time points p.i. In WT mice, serum IFN-a
peaked 48 hr p.i. and was sustained up to 3 days p.i. (Figure 2A).
In TxM/ mice, serum IFN-a was markedly reduced 16–24 hr
p.i. but was only slightly lower than in WT mice at later time
points. On the contrary, IFN-a was significantly diminished at
all time points and most severely at 2–3 days p.i. in MDA5/
mice. These data suggest that MDA5 is the major sensor of
ARM, whereas TLRs play an early, but limited, role. We next
determinedwhich TLR is responsible for the early IFN-I response
to ARM.We infectedWT, TRIF/, MyD88/, TxM/, TLR7/,
TLR2/, TLR3/, and TLR9/ mice with ARM and assessed
serum IFN-a at different time points p.i. Only TxM/, TLR7/
and MyD88/ mice had a significant reduction in serum
IFN-a, indicating that early production of IFN-I depends on the
TLR7/MyD88 pathway (Figures 2B and 2C).
Since CL13 has a broader cell tropism and replicative capacity
than ARM, we first asked whether the same sensors are required
and have a similar impact during the host response to this LCMV
strain. We infected WT, MDA5/, MyD88/, and TLR7/mice
with CL13 and determined serum IFN-a at various time points p.i.
Similarly to what we observed following ARM infection, MDA5/
mice lacked a sustained IFN-I response (Figure 2D), whereas
TLR7/ and MyD88/ mice had a noticeable defect only inCell Host & Microbe 11, 631–6the early IFN-I response (Figure 2E).
Thus, we conclude thatMDA5has amajor
role in the IFN-I response to LCMV. The
more limited and temporary impact of
TLR7 on IFN-a production is consistent
with the transient role of pDCs, which
detect LCMV through TLR7.
MDA5-DeficiencyDelaysCD8TCell
Responses to Acute LCMV and
Prolongs Viral Infection
Acute LCMV infection normally elicits
a robust effector CD8 T cell response fol-
lowed by contraction and generation of
a pool of memory CD8 T cells (Butz andBevan, 1998). Given its major impact on IFN-I production, we
asked whether the lack of MDA5 affects generation of LCMV-
specific CD8 T cells. We infected WT and MDA5/ mice
with ARM and monitored the induction of LCMV-specific
CD8 T cells in the spleen and peripheral blood over a 64-day
time span.
On day 8 p.i., WT mice had a substantial expansion of total
CD8 T cells, which represented, on average, 30% of spleno-
cytes, whereas CD8 T cells comprised approximately 10% of
splenocytes in MDA5/ mice (Figure 3A). In parallel with a
reduced percentage of total CD8 T cells, MDA5/ mice had
significantly lower percentages and numbers of LCMV GP33-41-
specific CD8 T cells than did WT mice (Figures 3B and 3C).
MDA5/ splenocytes killed EL4 cells pulsed with the GP33-41
peptide ex vivo (Figure S2), although less efficiently than WT
splenocytes, consistent with a lower representation of LCMV
GP33-41-specific CD8 T cells in the spleen. Thus, MDA5-
deficiency affected the number but not the function of virus-
specific CD8 T cells at early time points.
In WT mice, GP33-41-specific CD8 T cells waned in the spleen
and peripheral blood after day 8 p.i. and comprised approxi-
mately 3% of total CD8 T cells on day 64 p.i. (Figures 3D–3F).
In contrast, in MDA5/ mice, the frequency and absolute
numbers of GP33-41-specific CD8 T cells gradually increased
over time in both blood and spleen, peaking between day 16
and day 32 p.i. Contraction of GP33-41-specific CD8 T cells in
MDA5/mice occurred only after day 32 p.i. and reached levels
similar to those of WT mice on day 64 p.i. (Figures 3D–3F).
Delayed expansion of CD8 T cells in MDA5/mice was associ-
ated with deferred expression of the killer cell lectin-like receptor
(KLRG1), a marker for T cell activation (Blaser et al., 1998)42, June 14, 2012 ª2012 Elsevier Inc. 633
Figure 3. Impact of MDA5 Deficiency on the
CD8 T Cell Response and Viral Clearance
during ARM Infection (See Also Figure S2)
(A) Frequencies of splenic CD8 T cells on day 8 p.i.
(B and C) Frequencies (B) and absolute numbers
(C) of splenic LMCV GP33-41-specific CD8 T cells
on day 8 p.i.
(D and E) Frequencies (D) and absolute numbers
(E) of splenic LMCVGP33-41-specific CD8 T cells at
various time points during ARM infection.
(F) Frequencies of LMCV GP33-41-specific CD8
T cells in peripheral blood during ARM infection.
(G) KLRG1 expression on GP33-41-specific CD8
T cells in spleens of WT (black histogram) and
MDA5/ (gray histogram) mice.
(H and I) Viral burden in spleens was examined by
plaque assay (H) and qPCR for glycoprotein (GP)
RNA (I) at various time points p.i.
(J and K) Frequencies of CD127+ cells (J) and
CD62L+ cells (K) among LMCV GP33-41-specific
CD8 T cells in spleens on day 64 p.i.
(L) PurifiedCD8 T cells (2 x 106) fromARM-infected
WT and MDA5/ mice on day 64 p.i. were
transferred into naiveWTmice.Mice were infected
(ARM) or not (Mock) with 3 x 105 ARM 16 hr post
transfer; control mice (CTL), which did not receive
T cells, were also infected. Viral burden in spleens
was analyzed on day 2.5 p.i. The dashed lines
represent the minimum level of detection. Three
to twelve mice were analyzed in each experi-
ment. Error bars represent the mean ± SEM.
*** = p < 0.001; ** = p < 0.01; * = p < 0.05, Student’s
t test.
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MDA5/ mice. While no virus was detectable in the spleen of
WT mice by plaque assay on day 10 p.i., viral elimination was
delayed until day 16 p.i. in MDA5/mice (Figure 3H). To detect
possible ongoing viral replication below the limit of detection of
the plaque assay at later time points, we measured LCMV GP
RNA in the spleen. While LCMV GP RNA was below the level
of detection in the spleens of infected WT mice on day 32 p.i.,
spleens of MDA5/ mice contained on average 20 copies of634 Cell Host & Microbe 11, 631–642, June 14, 2012 ª2012 Elsevier Inc.GP RNA per 106 copies of GAPDH RNA
(Figure 3I). However, by day 64 p.i.,
LCMV GP RNA was not detected in either
group.
Finally, we asked whether MDA5 defi-
ciency alters generation of the memory
CD8 T cell pool at late time points after
ARM infection. On day 64 p.i., WT and
MDA5/ mice had similar percentages
of splenic GP33-41-specific CD8 T cells
expressing the memory markers CD127,
CD62L, and CD44 (Figures 3J and 3K
and data not shown), suggesting that
MDA5 deficiency did not affect the size
of the memory CD8 T cell pool. Moreover,
we asked whether memory CD8 T cells
from MDA5/ mice are as protective as
their WT counterparts in mice challengedwith LCMV. CD8 T cells were purified from the spleens ofWT and
MDA5/ mice on day 62 p.i. and adoptively transferred into
naive mice, which were subsequently challenged with ARM.
Mice that received CD8 T cells from either WT or MDA5/
mice were equally effective in reducing viral titers, in comparison
to control mice that did not receive CD8 T cells (Figure 3L). These
results indicate that MDA5 deficiency did not significantly alter
the generation of memory CD8 T cells or their ability to protect
mice from secondary challenge. Altogether, our data suggest
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CD8 T cells and clearance of ARM infection. However, lack of
MDA5 does not induce long-term CD8 T cell defects and viral
persistence, indicating that alternativemechanisms compensate
for the lack of MDA5 since CD8 T cell responses are preserved
and the virus is cleared.
Blockade of IL-12 Does Not Exacerbate the Delayed
anti-ARM CD8 T Cell Response in MDA5–/– Mice
Although lack of MDA5 delays the CD8 T cell response to acute
LCMV infection, the infection is eventually cleared, suggesting
that other signals compensate for lack of MDA5. It has been
shown that in the absence of IFN-I signaling, IL-12 production
is elevated, providing an alternative signal that facilitates CD8
T cell responses (Cousens et al., 1999). Therefore, we first inves-
tigated the impact of IL-12 on CD8 T cell response against ARM
in MDA5/ mice. We compared the levels of IL-12p35 mRNA
in the spleen and IL-12p40 protein in the serum of WT and
MDA5/ mice early during ARM infection. TxM/ mice were
also included as controls, as TLRs are known to promote IL-12
responses to viral infection (Pichlmair and Reis e Sousa, 2007;
Takeuchi and Akira, 2010). We found no differences in IL-12
levels between WT and MDA5/ mice. In contrast TxM/
mice had markedly reduced amounts of IL-12p40 in the serum
as well as very low IL-12p35 mRNA expression in the spleen
(Figures S3A and S3B). Further indicating that IL-12 does not
compensate for IFN-I deficiency in MDA5/ mice, antibody-
mediated blockade of IL-12 in MDA5/ mice did not augment
the disparity between MDA5/ and WT mice in terms of their
capacity to generate LCMV-specific CD8 T cells (data not
shown). Similarly, IL-12 blockade did not impair the long-term
capacity of virus-specific CD8 T cells to produce TNF-a and
IFN-g in either MDA5/ or WT mice (Figures S3C and S3D).
Loss of CD4 T Cell Help and MDA5-Mediated IFN-I
Production Leads to CD8 T Cell Exhaustion during ARM
Infection
We next asked whether CD4 T celI help compensates for lack
of MDA5 in inducing anti-LCMV CD8 T cell responses and viral
clearance. It has been shown that CD8 T cell responses to
ARMdo not require CD4 T cell help, since CD4/mice can clear
infection (Ahmed et al., 1988; Battegay et al., 1994; Matloubian
et al., 1994; Rahemtulla et al., 1991). Consistent with this,
depletion of CD4 T cells with the GK1.5 antibody in WT mice
had little impact on the priming and expansion of LCMV-specific
CD8 T cells on day 8 p.i. or their cytokine production (Figures
4A–4C). In the short term (8 days p.i.) CD4 T cell-depletion in
MDA5/ mice only caused a minor but statistically significant
reduction of GP33-41-specific CD8 T cells compared to nonde-
pleted MDA5/ mice. Additionally, the percentage of IFN-g+
TNF-a+ CD8 T cells was similar in CD4 T cell-depleted and non-
depleted MDA5/ mice (Figure 4C).
However, in the long term, CD4 T cell depletion in MDA5/
had a major impact on CD8 T cells. On day 32 p.i., GK1.5 treat-
ment led to a further reduction of GP33-41-specific CD8 T cells in
MDA5/ mice (Figures 4D–4F). More importantly, a marked
proportion of GP33-41-specific CD8 T cells in GK1.5-treated
MDA5/mice had lost the ability to produce TNF-a in response
to peptide stimulation (Figures 4G and 4H), indicating that thoseCell HCD8 T cells were functionally exhausted (Wherry, 2011). In
contrast, TNF-a and IFN-g production was only slightly reduced
in nondepleted MDA5/ mice. CD8 T cells in MDA5/ mice
depleted of CD4 T cells displayed other characteristics associ-
ated with exhaustion, such as PD-1 expression (Wherry, 2011)
(Figure 4I). Finally, while WT mice treated with GK1.5 and
MDA5/ mice were able to clear infection, GK1.5-treated
MDA5/ mice had relatively high viral burdens in the spleen
on day 32 p.i. (Figure 4J). Thus, while an isolated defect in
MDA5 results in a delayed CD8 T cell response with limited func-
tional consequences, the lack of both MDA5 and CD4 T cell help
converts an acute LCMV infection into a chronic infection asso-
ciated with marked CD8 T cell exhaustion.
Early Blockade of IFN-I Signaling Impaired Antiviral
CD8 T Cells beyond MDA5 Deficiency
Because the MDA5 pathway stimulates production of both IFN-I
and inflammatory cytokines, we wanted to dissociate the contri-
bution of IFN-I from the potential contribution of inflammatory
cytokines on the induction of anti-ARM CD8 T cells. Therefore,
to mimic the lack of early IFN-I response, we treated WT mice
with a single injection of an antibody that blocks the receptor
for IFN-I (IFNAR) at 16 hr p.i. Early IFNAR blockade was carried
out with or without CD4 T cell depletion. Whereas CD4 depletion
alone had little effect, combined blockade of IFNAR signaling
and CD4 depletion resulted in reduced numbers of GP33-41-
specific CD8 T cells, almost complete abrogation of their
capacity to produce both IFN-g and TNF-a, and increase in
PD-1 expression (Figures S3E–S3H). This provides further
evidence that CD8 T cell exhaustion in ARM infection results
from a lack of early IFN-I response during the induction of CD8
T cell response combined with absence of CD4 T cell help. Inter-
estingly, althoughMDA5 deficiency alone did not induce obvious
functional exhaustion of CD8 T cells, IFNAR blockade induced
a detectable reduction of IFN-g and TNF-a production and
modest increase in PD-1 expression (Figures S3E–S3H). These
results suggest that in the absence of MDA5, LCMV infection
elicits residual amounts of IFN-I, which, combinedwithCD4Tcell
help, prevent functional exhaustion of virus-specific CD8 T cells.
IFN-I Responses Are More Rapidly Impaired by CL13
Infection than by ARM Infection
Our data show that when IFN-I responses are impaired, as
they are in MDA5/ mice, host responses become reliant on
CD4 T cell help to prevent persistent ARM infection. Since
CL13 infection impairs CD4 T cell help (Brooks et al., 2005), we
asked whether IFN-I responses are concomitantly reduced,
such that the combined defect results in viral persistance.
Although we had observed that IFN-a responses to ARM and
CL13 have similar kinetics (see Figure 2), we hypothesized that
the magnitude of IFN-a response was different during the two
infections. This possibility could not be easily excluded since
mice are usually infected with different inoculi of ARM and
CL13 (3 x 105 versus 3 x 106 PFU/mouse respectively) and
different routes (i.p. versus i.v.); therefore, the amounts of IFN-a
induced in the serum cannot be directly compared. Thus, we
infected WT mice i.v. with 3 x 106 PFU of ARM or CL13 and
measured serum IFN-a at different time points. As previously
observed, IFN-a peaked on day 2 in both infections and thenost & Microbe 11, 631–642, June 14, 2012 ª2012 Elsevier Inc. 635
Figure 4. Impact of CD4 T Cell Help on CD8 T Cells during ARM Infection in the Absence of MDA5 (See Also Figure S3)
(A–J) Mice were treated with isotype control mAb (ISO CTL) or GK1.5 mAb and infected with ARM. In (A–C) Analysis on day 8 p.i. Frequencies (A) and absolute
numbers (B) of splenic GP33-41-specific CD8 T cells and (C) frequencies of IFN-g- and TNF-a-producing CD8 T cells after ex vivo GP33-41 peptide stimulation are
shown. (D–J) Analysis on day 32 p.i. Frequencies (D) and absolute numbers (E) of splenic GP33-41-specific CD8 T cells are shown. (F and G) Flow cytometric
determination and (H) percentages of splenic IFN-g- and TNF-a-producing CD8 T cells after ex vivo GP33-41 peptide stimulation. (I) PD-1 expression
(black histogram) among GP33-41-specific CD8 T cells. Gray histograms show PD-1 expression on naive CD8 T cells. (J) Viral burden in spleens was
also measured. Data are representative of two independent experiments with 3–5 mice/group in each experiment. Error bars represent the mean ± SEM.
**** = p < 0.0001; *** = p < 0.001; ** = p < 0.01; * = p < 0.05, Student’s t test.
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than ARM-infected mice (Figure 5A).
It has been shown that LCMV nucleoprotein binds to and
inhibits MDA5 and RIG-I in vitro (Zhou et al., 2010). Thus, it636 Cell Host & Microbe 11, 631–642, June 14, 2012 ª2012 Elsevierseemed possible that CL13 is more efficient than ARM at block-
ing MDA5 because of its higher rate of replication. However, the
RNA levels of nucleoprotein and glycoprotein were similar in
CL13- and ARM-infected spleens on day 4 p.i. (Figure 5B).Inc.
Figure 5. IFN-I Production, Viral Replication, and
CD8 T Cell Responses during ARM and CL13
Infections
(A and B) Serum IFN-a (A) and LCMV NP and GP RNA load
(B) in spleens of WTmice infected with 3 x 106 PFU of ARM
or CL13 i.v. were measured.
(C and D) GP33-41-specific CD8 T cells in peripheral blood
(C) and spleen (D) were analyzed on day 8 p.i. Data are
representative of at least two independent experiments
with a minimum of 3 mice/group. Error bars represent the
mean ± SEM. *** = p < 0.001; ** = p < 0.01, Student’s t test.
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through alternative mechanisms.
In parallel with amore rapid decline in IFN-a, WTmice infected
with CL13 had fewer LCMV-specific CD8 T cells than mice
infected with ARM on day 8 p.i. in both blood and spleen
(Figures 5C and 5D). Moreover, the generation of anti-LCMV-
specific CD8 T cells was more severely reduced in CL13- than
in ARM-infected MDA5/ mice, indicating that generation of
CD8 T cells is more IFN-I-dependent during CL13 than during
ARM infection. We speculate that while reduction of the IFN-I
response during ARM infection in MDA5/ mice is compen-
sated by CD4 T cell help (see Figure 4), this is less likely to occur
during CL13 infection because the CD4 T cell response is known
to be partially impaired in this situation (Brooks et al., 2005).
Indeed, during CL13 infection, activated CD4 T cells become
susceptible to NK cell-mediated lysis, which dampens CD4
T cell responses (Waggoner et al., 2012).
Early Administration of IFN-I during Chronic LCMV
Infection Prevents Viral Persistence and CD8 T Cell
Exhaustion
Because the early IFN-I responsewas lower inmice infectedwith
CL13 than in those infected with ARM, we asked whether IFN-I
treatment early during CL13 infection can improve subsequent
CD8 T cell responses. We administered 15,000 U of recombinant
IFN-b and IFN-a5 to WT mice i.v. on day 3 and day 5 after
infection with CL13 and analyzed peripheral blood and splenic
CD8 T cells on day 8 p.i. IFN-I treatment significantly augmented
the frequency and absolute numbers of GP33-41-specific CD8
T cells in WT mice (Figures 6A and 6B). Administration of IFN-I
also improved CD8 T cell responses to CL13 in MDA5/ mice,
amplifying GP33-41-specific CD8 T cells to the levels seen in
IFN-I-treated WTmice (Figure 6C). Exogenous IFN-I was equally
effective when administered on day 3 and day 4 or on day 2Cell Host & Microbe 11through day 5, but less effective on day 2 and
day 3 (Figure 6C), and was completely ineffec-
tive beyond one week of infection (data not
shown), consistent with a recent study (Audige´
et al., 2011). Interestingly, the window of IFN-I
effectiveness coincides with IFN-I decline
following infection with CL13 and the priming
of CD8 T cells, suggesting that priming of CD8
T cell responses requires sustained IFN-I during
the initial phase of the infection. Depletion of
CD4 T cells did not diminish the efficacy ofIFN-I treatment in enhancing CD8 T cell response (Figures 6D
and 6E), further confirming that CD4 T cell help is not necessary
in the presence of optimal levels of IFN-I. Administration of heat-
inactivated IFN-I had no effect on CD8 T cells (Figure S4A),
excluding a putative adjuvant effect of bacterial components
contaminating IFN-I preparations. In addition, IFN-I treatment
of TCRbd/ mice did not affect viral titers in the spleen, indi-
cating that the amount of IFN-I administered was not sufficient
to directly inhibit viral replication (Figure S4B).
Finally, we analyzed CD8 T cell responses in IFN-I-treated
mice on day 32 after CL13 infection. Similarly to the primary
response on day 8, IFN-I-treated mice had consistently higher
frequencies and absolute numbers of GP33-41-specific CD8
T cells in the spleen (Figures 7A–7C). Moreover, while GP33-41-
specific CD8 T cells in WT mice were unable to produce TNF-a
and expressed PD-1, GP33-41-specific CD8 T cells from IFN-I-
treated mice remained polyfunctional and did not express
PD-1 (Figures 7D–7F), confirming that early IFN-I treatment
effectively prevented CD8 T cell exhaustion. We also asked
whether IFN-I treatment improved the ability of GP33-41-specific
CD8 T cells to kill target cells in vivo. Cytotoxicity was evaluated
in CL13-infected mice with or without IFN-I treatment on day 32
p.i. For target cells, naive splenocyteswere either pulsedwith the
GP33-41 peptide or not pulsed, and each population was labeled
with a different concentration of carboxyfluorescein diacetate
succinimidyl ester (CFSE) in order to distinguish the two. IFN-I-
treated mice were more efficient at clearing peptide-pulsed cells
than were untreated mice (Figures 7G and 7H). Furthermore,
IFN-I-treated mice had completely cleared infection on day 32
p.i., while high viral loads were still detectable in the spleens of
untreated mice (Figure 7I). Altogether, our data suggest that
therapeutic administration of IFN-I within a critical time frame
after infection (day 3–5 p.i.) effectively prevents CD8 T cell
exhaustion and establishment of chronic infection., 631–642, June 14, 2012 ª2012 Elsevier Inc. 637
Figure 6. IFN-I Treatment Boosts the CD8 T Cell Response during
CL13 Infection (See Also Figure S4)
(A and B) CL13-infected WTmice were treated with IFN-I or not (UT) on days 3
and 5 p.i. Numbers of GP33-41-specific CD8 T cells were determined in
peripheral blood (PBL) (A) and spleen (B) on day 8 p.i.
(C) MDA5/ andWTmice were UT or treated with IFN-I on the indicated days
p.i. GP33-41-specific CD8 T cells were analyzed in PBL on day 8 p.i.
(D and E) WT mice were treated with control (ISO CTL) or GK1.5 mAb on
days1 and +1 p.i. IFN-I was administered or not on days 3 and 5 p.i. GP33-41-
specific CD8 T cells were analyzed in PBL (D) and spleen (E) on day 8 p.i.
Data represent at least two independent experiments with 2–5 mice/group.
**** = p < 0.0001; *** = p < 0.001, Student’s t test.
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In this study, we defined the pathways that elicit an IFN-I
response during acute and chronic LCMV infection and their
relative impact on CD8 T cell responses. As yet, there is no
consensus regarding the role of pDCs in LCMV infection. An
early report indicated that the IFN-I response to LCMV is pDC-
independent (Dalod et al., 2002). However, a more recent study
placed emphasis on the role of pDCs in inducing both IFN-I and
CD8 T cell responses to acute LCMV (Jung et al., 2008). Mice
with a conditional deletion of the transcription factor E2-2 in
CD11c+ cells lack pDCs, which results in impaired control
of chronic LCMV infection due to defective antiviral CD4 T cell638 Cell Host & Microbe 11, 631–642, June 14, 2012 ª2012 Elsevierresponses (Cervantes-Barragan et al., 2012). Taking advantage
of a mouse model of inducible pDC depletion, we found that
neither transient nor chronic depletion of pDCs had an appre-
ciable effect onCD8 T cell responses or viral burden during either
acute or chronic LCMV infection. pDCs made an early but
transient contribution to the systemic IFN-I response to LCMV,
probably because they rapidly disappeared from the spleen,
perhaps due to IFN-I-induced apoptosis (Swiecki et al., 2011).
The early contribution of pDCs to the IFN-I response to LCMV
is in agreement with a report by Macal et al. (2012) in this issue
of Cell Host & Microbe. Similarly, in another report in this issue
of Cell Host & Microbe, the TLR7 pathway was responsible for
early production of IFN-I, but had no major impact on the magni-
tude of the IFN-I response and viral burden in the spleen until day
30 p.i. (Walsh et al., 2012). Interestingly, the lack of TLR7 facili-
tates persistence of CL13 infection in brain and kidney at later
time points (Walsh et al., 2012). Thus, lack of TLR7 may have
broader impact than lack of pDCs on anti-LCMV responses,
especially in chronic infection.
In contrast, MDA5 was the major trigger of IFN-I in response
to both acute and chronic LCMV infections, made evident by
markedly reduced IFN-I production in infected MDA5/ mice.
Because activation of MDA5 requires the presence of viral
RNA in the cytosol, it is likely that LCMV-infected cells are the
major source of IFN-I. Supporting this conclusion, depletion of
macrophages, which are a preferential target of ARM, results
in almost complete abrogation of IFN-I (Borrow et al., 1995;
Louten et al., 2006; Mu¨ller et al., 2002). Since CL13 infects not
only macrophages but also hematopoietic progenitors, DCs,
and fibroblasts (Bergthaler et al., 2010; Borrow et al., 1995;
Macal et al., 2012; Mueller et al., 2007; Sevilla et al., 2000,
2004), IFN-I is probably generated by a wide array of cells during
CL13 infection. Consistent with previous studies (Borrow et al.,
2010; Lee et al., 2009a; Zuniga et al., 2008), we found that the
systemic IFN-I response to LCMV rapidly declined within the first
week of infection, whether the virus was cleared (ARM) or per-
sisted (CL13). Thus, waning of the systemic IFN-I response did
not reflect viral clearance, but rather the capacity of LCMV to
actively inhibit the IFN-I response. Inhibition may be mediated
by NP, which was recently reported to interfere with IRF3 activa-
tion (Martı´nez-Sobrido et al., 2006) as well as bind to and inhibit
MDA5 and RIG-I (Zhou et al., 2010). Moreover, CL13 may down-
modulate the IFN-I response through additional immunosup-
pressive mechanisms.
TheMDA5pathwaywasnotonly important for IFN-I production
but also for CD8 T cell responses. Because IFN-I has been shown
to promote the expansion of LCMV-ARM-specific CD8 T cells
(Kolumam et al., 2005; Thompson et al., 2006; van den Broek
et al., 1995b), it was not unexpected to observe an initial reduc-
tion inCD8 T cells inMDA5/mice. However, wewere surprised
to see that CD8 T cells expanded even more in MDA5/ than in
WT mice at later time points and ultimately controlled viral
infection. This prolonged CD8 T cell response is probably due
to sustained viral replication and viral antigen presentation and
is reminiscent of what has been reported in mice infected with
murine cytomegalovirus (MCMV) and lacking efficient NK cell
responses (Andrews et al., 2010; Lee et al., 2009b).
The ultimate control of viral infection in MDA5/ mice sug-
gested compensation by other mechanisms. While we excludedInc.
Figure 7. IFN-I Treatment Prevents CD8 T
Cell Exhaustion andChronic LCMV Infection
(A–E) CL13-infected WT mice were treated with
IFN-I or not (UT) on days 3 and 5 p.i. Spleens of
UT and IFN-I-treated mice were analyzed on day
32 p.i. for frequencies (A and B) and absolute
numbers (C) of GP33-41-specific CD8 T cells. In
(D and E) IFN-g and TNF-a production by CD8
T cells after ex vivo GP33-41 peptide stimulation
was also analyzed. In (F) PD-1 expression (black
histogram) among GP33-41-specific CD8 T cells
was determined. Gray histograms indicate PD-1
expression of naive CD8 T cells. (G and H) In vivo
cytotoxicity of virus-specific CD8 T cells was per-
formed in naive or CL13-infected mice with or
without IFN-I treatment. (I) Spleen viral load in
CL13-infected mice with or without IFN-I treat-
ment. Data represent at least two independent
experiments with 2–5 mice/group. Error bars re-
present themean ± SEM. **** = p < 0.0001; *** = p <
0.001; ** = p < 0.01; * = p < 0.05, Student’s t test.
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Early Antiviral IFN-I Halts CD8 T Cell Exhaustiona role for IL-12, CD4 T cell depletion combined with MDA5 defi-
ciency did result in CD8 T cell exhaustion and persistent infection
characteristic of CL13 infection. Thus, IFN-I and CD4 T cell help
synergize to promote effective CD8 T cell responses against
ARM and prevent viral persistence. Corroborating this, a recent
report showed that IFN-I can compensate for CD4 help in
inducing CD8 T cell responses during vaccinia infection (Wiesel
et al., 2011). Because IL-12 did not compensate for the lack of
IFN-I, we surmise that CD4 T cell help for CD8 T cells is indepen-Cell Host & Microbe 11, 631–6dent of IL-12, but might be mediated by
IL-2 (Ridge et al., 1998; Williams et al.,
2006).
The concurrent roles for IFN-I and CD4
T cell help in effectively controlling ARM
infection provide insight into the mecha-
nisms responsible for viral persistence
and CD8 T cell exhaustion during CL13
infection in WT mice. We found that
CL13 inhibits the IFN-I response more
effectively than does ARM. This may
reflect the high replicative capacity of
CL13 as well as its ability to infect and
inhibit a broader array of cells than
ARM, including DCs and stromal cells
(Bergthaler et al., 2010; Borrow et al.,
1995; Macal et al., 2012; Mueller et al.,
2007; Sevilla et al., 2000, 2004). Addition-
ally, CL13 impairs CD4 T cell responses,
due partly to induction of IL-10 (Brooks
et al., 2005) and partly to NK cell-
mediated lysis of activated CD4 T cells
(Waggoner et al., 2012). Thus, we envi-
sion that CL13 may promote CD8 T cell
exhaustion and establish chronic infec-
tion by jeopardizing both early IFN-I
responses and CD4 T cell help to CD8
T cells. Other factors, such as the in-
creased viral loads and the presence ofinhibitory cytokines may also contribute to the dysfunctional
antiviral CD8 T cell response in CL13 infection.
Importantly, IFN-I treatment on days 3 and 4 p.i. bolstered the
CD8 T cell response and led to clearance of CL13 infection.
Reconstitution of optimal levels of IFN-I was equally effective
in WT and MDA5/ mice, probably because exogenous IFN-I
can compensate for the CL13-mediated inhibition of IFN-I as
well as for MDA5 deficiency. IFN-I may also boost CD4 T helper
cells in both WT and MDA5/ mice (Havenar-Daughton et al.,42, June 14, 2012 ª2012 Elsevier Inc. 639
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Early Antiviral IFN-I Halts CD8 T Cell Exhaustion2006). IFN-I treatment during CL13 infection was effective during
a narrow window of time that coincides with the decline of the
IFN-I response and priming of CD8 T cells. Thus, the impact of
disparate cellular and molecular sources of IFN-I on CD8
T cell-mediated control of viral infection depends on the timing
and duration of the IFN-I response engendered and the rate of
viral replication. IFN-I production by pDCs is too little and too
transient to enable CD8 T cell responses to LCMV, but may be
sufficient to control viruses that replicate more slowly than
LCMV or are inoculated in lower amounts. The magnitude and
duration of MDA5-induced IFN-I is adequate to elicit effective
CD8 T cell responses and control infection by ARM, but not
CL13, which replicates more rapidly and effectively than ARM,
impairing both MDA5 and CD4 T cell function. Thus, a sup-
plementary source of IFN-I is needed to promote CD8 T cell-
mediated control of CL13 infection.
Recombinant IFN-a is currently used to treat chronic
hepatitis C virus and hepatitis B virus infections because of its
direct antiviral properties (Gonzalez and Keeffe, 2011). Our
study indicates that IFN-I also promotes the generation of
antiviral CD8 T cells that facilitate viral clearance during
chronic infection. We predict that IFN-I would be particularly
effective if administered during the acute phase of infection,
concurrent with CD8 T cell priming and expansion. Moreover,
IFN-I treatment may be effective in conjunction with the admin-
istration of ‘‘therapeutic’’ vaccines to induce CD8 T cells that
reduce the viral set point. Thus, the rescue of CD8 T cell
responses may be a benchmark for IFN-I treatment of certain
viral infections.
EXPERIMENTAL PROCEDURES
Mice, Viral Infections, Treatment with DT and Recombinant IFN-I
Knockout mice (listed in Supplemental Experimental Procedures), BDCA2-
DTR transgenic mice, and WT C57BL/6 control mice were age- and gender-
matched and bred in the same room. DT (Sigma-Aldrich) was injected i.p.
into BDCA2-DTR transgenic mice as previously described (Swiecki et al.,
2011). IFN-I treatment consisted of i.v. injections of 15,000 U of recombinant
mouse IFN-b and IFN-a5 (kindly provided by D. Fremont). Mice were infected
with 3 x 105 PFU of ARM i.p. or 3 x 106 PFU of CL13 i.v. For the comparison of
IFN-I production,micewere infected i.v. with 3 x 106 PFU of ARMor CL13. Viral
burden in the spleen was determined by plaque assay and qPCR. Animal
studies were approved by the Washington University Animal Studies
Committee.
Quantitative PCR and ELISA
Relative levels of IL-12p35, LCMV NP, and GP RNA expression were deter-
mined by qPCR, using SYBR Green PCR master mix (Bio-Rad Laboratories)
and an ABI7000 machine (Applied Biosystems). Primers are described in
Supplemental Experimental Procedures. IFN-a and IL-12p40were determined
by ELISA (PBL Interferon Source, eBioscience).
Flow Cytometry
LCMV-specific CD8 T cells were detected with H-2DbGP33-41 tetramers
(Beckman-Coulter). Additional reagents used for flow cytometry are listed in
Supplemental Experimental Procedures.
Determination of CD8 T Cell Polyfunctionality
Spleen cells from LCMV-infected mice were cultured for 6 hr in the presence
of GP33-41 peptide (5–10 mg/ml) and GolgiPlug (BD Biosciences). Intracellular
IFN-g and TNF-a production by CD8 T cells was determined by flow
cytometry. Formulas for calculation of polyfunctional CD8 T cells are included
in Supplemental Experimental Procedures.640 Cell Host & Microbe 11, 631–642, June 14, 2012 ª2012 ElsevierCytotoxicity Assays
In vitro assays consisted of a standard 51Cr release assay. Effector and
target cells are specified in Supplemental Experimental Procedures. In vivo
cytotoxicity of CD8 T cells was determined by adoptively transferring 5 x 106
GP33-41 peptide pulsed naive splenocytes labeled with CFSE at 5 mM and
5 x 106 unpulsed naive splenocytes labeled with CFSE at 1 mM. Spleens
were harvested 7 hr post transfer and the ratio between GP33-41 pulsed cells
(CFSEhi) and unpulsed cells (CFSElo) was determined by flow cytometry.
Antibody-Mediated Depletion and Neutralization
Purified GK1.5 mAb and neutralizing IL-12mAb (10F6) were used as described
previously (Zajac et al., 1998; Mattner et al., 1997). MAR1 or isotype control
mAb was administered i.p. 16 hr p.i. (2 mg/mouse).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism (GraphPad
Software). The statistical significance of differences in mean values was
analyzed with an unpaired, two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.chom.2012.05.003.
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